Vintafolide
Vintafolide
Vintafolide (pronunciation: vin-ta-fo-lide) is a small molecule drug conjugate that targets cancer cells. It was developed by Endocyte and Merck & Co. for the treatment of various types of cancer, including ovarian cancer and lung cancer.
Etymology
The name "Vintafolide" is derived from the components of the drug: "vin" for vinblastine, a chemotherapy drug; "ta" for targeting agent; and "folide" for folic acid, which the drug uses to target cancer cells.
Mechanism of Action
Vintafolide works by binding to the folate receptor, which is overexpressed in many types of cancer cells. The drug is then internalized by the cell, where it releases the chemotherapy drug vinblastine to kill the cell.
Clinical Trials
Vintafolide has been tested in several clinical trials for the treatment of ovarian cancer and lung cancer. However, in 2014, the drug failed a phase III clinical trial for ovarian cancer, leading Merck & Co. to discontinue its development.
Related Terms
- Vinblastine: A chemotherapy drug used in the treatment of various types of cancer.
- Folate receptor: A cell surface receptor that binds folic acid and is overexpressed in many types of cancer cells.
- Ovarian cancer: A type of cancer that begins in the ovaries.
- Lung cancer: A type of cancer that begins in the lungs.
External links
- Medical encyclopedia article on Vintafolide
- Wikipedia's article - Vintafolide
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski